PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30094101-0	2018	Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of Integrin beta2/FAK signaling pathway in ovarian cancer.	bufalin	0-7	integrin subunit beta 2	Homo sapiens	93-107	
30094101-5	2018	Mechanistically, bufalin exerted its anti-tumor effect by targeting ITGB2/FAK signaling pathway in vitro and in vivo, which could be rescued by the introduction of ITGB2 cDNA in ovarian cancer cells.	bufalin	17-24	integrin subunit beta 2	Homo sapiens	68-73	
30094101-5	2018	Mechanistically, bufalin exerted its anti-tumor effect by targeting ITGB2/FAK signaling pathway in vitro and in vivo, which could be rescued by the introduction of ITGB2 cDNA in ovarian cancer cells.	bufalin	17-24	integrin subunit beta 2	Homo sapiens	164-169	
30094101-6	2018	These findings provide evidence that bufalin inhibited cellular glycolysis-induced cell growth and proliferation through repression of the ITGB2/FAK pathway, indicating that bufalin may be developed as a chemotherapeutic agent to treat ovarian cancer.	bufalin	37-44	integrin subunit beta 2	Homo sapiens	139-144	
30094101-6	2018	These findings provide evidence that bufalin inhibited cellular glycolysis-induced cell growth and proliferation through repression of the ITGB2/FAK pathway, indicating that bufalin may be developed as a chemotherapeutic agent to treat ovarian cancer.	bufalin	174-181	integrin subunit beta 2	Homo sapiens	139-144